BackArriVent BioPharma Overview

ArriVent BioPharma Total Current Liabilities

Latest total current liabilities for AVBP: $28M.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$27.84M
41.80% YoYΔ $8.21M vs prior year quarter

Peer trimmed avg / median

Loading

ArriVent BioPharma Total Current Liabilities History

Loading

ArriVent BioPharma vs. peers: Total Current Liabilities Comparison

Loading

ArriVent BioPharma Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

ArriVent BioPharma (AVBP) FAQ

As of the most recent data (June 2026), AVBP shows a total current liabilities of $28M. That compares with $20M in the prior-year period — up 41.8% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AVBP's total current liabilities is now $28M (was $20M) — a 41.8% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether ArriVent BioPharma is outperforming or lagging.

Tracking AVBP's total current liabilities over time shows whether ArriVent BioPharma is scaling, shrinking, or reshaping that part of the business. The current reading is $28M That compares with $20M in the prior-year period — up 41.8% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has ArriVent BioPharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $28M) with ownership activity and broader fundamentals.